Company profile

ScheBo^® • Biotech AG is an innovative biotech company that is active in the fields of drug development and the development, production and marketing of diagnostics.

ScheBo^® • Biotech AG is developing novel cancer therapies for the treatment of various solid tumours and their metastases.

The manufacturing of our leading products is matched exactly to satisfy of our customers.

ScheBo^® • Biotech AG was founded by the biochemists and molecular biologists Ursula Scheefers-Borchel, Ph.D., and Hans Scheefers, Ph.D.

Continuous innovation, strong customer focus and creative problem solving have made ScheBo^® • Biotech AG a worldwide leading manufacturer of unique products. We invite you to convince yourselves of the advantages of ScheBo^® • Biotech AG. Come and see!

ScheBo^® • Biotech AG
Netanyastrasse 3 / 35394 Giessen / Germany
Phone: +49-(0)641-4996-0 /Fax: +49-(0)641-4996-77
eMail: schebo@schebo.com / Internet: www.schebo.com

Board of Executives of ScheBo^® • Biotech AG:
Ursula Scheefers-Borchel, Ph.D.
Hans Scheefers, Ph.D.
René M. Kröger, Ph.D.

Foundation (year): 1989

Areas of Activity: VD-Diagnostics, Drug development

Biological Patents:
ScheBo^® • BiotechAG holds many national and international patents in the above fields

External Collaborations:
ScheBo^® • Biotech AG has academic alliances with several universities and university hospitals in Europe, USA, Japan, England, Italy, Israel and Canada.

Subsidiaries:

• ScheBo^® • Biotech UK Ltd., founded: 1999
• ScheBo^® • Biotech USA Inc., founded: 2001

The company:

• is specialiced in the manufacturing of monoclonal antibodies against a variety of antigens, the development of routine test procedures (e.g. ELISA systems, biosensors) and the identification and isolation of target proteins,
• is completely privately funded and hence independent,
• operates internationally,
• offers innovative products which have world-wide a unique position in the field of clinical diagnostics.

World-wide Innovations:

R&D and manufacturing led to the successful launch and sales of the following products:

• ScheBo^® • Pancreatic Elastase 1 Serum Test
  (launched in 1993)
• ScheBo^® • Pancreatic Elastase 1 Stool Test
  (launched in 1994)
• ScheBo^® • Tumor M2-PK™ EDTA Plasma Test*
  (launched in 1998)
• ScheBo^® • Elastase Canine Test
  (launched in 1999)
• ScheBo^® • Brainostic™ Western Blotting Test
  (launched in 2000)
• ScheBo^® • Quick-Prep^®
  (launched in 2002)
• ScheBo^® • Tumor M2-PK™ Stool Test Laboratory*
  (launched in 2003)
• ScheBo^® • Tumor M2-PK™ Stool Test Pharmacy*
  (launched in 2003)
• ScheBo^® • Pancreatic Elastase 1 Stool Test (fast)
  (launched in 2004)
• ScheBo^® • Brainostic™ GFAP ELISA
  (launched in 2004)
• ScheBo^® • Pancreatic Elastase Serum Test (fast)
  (launched in 2005)
• ScheBo^® • M2-PK Quick™ -Test (lateral flow test)
  (launched in 2007)

*Info: www.darmkrebstest.de; www.metabolic-database.com
Link to the VBU Guide of German Biotech R & D Companies!